Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

The application of atxn2l as a marker for auxiliary evaluation of secondary resistance to oxaliplatin in gastric cancer

An oxaliplatin and secondary technology, which is applied in the function and application of genes and proteins, and can solve problems affecting the efficacy of chemotherapy, etc.

Active Publication Date: 2021-11-30
NANFANG HOSPITAL OF SOUTHERN MEDICAL UNIV
View PDF5 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, oxaliplatin resistance often occurs, affecting the efficacy of chemotherapy

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • The application of atxn2l as a marker for auxiliary evaluation of secondary resistance to oxaliplatin in gastric cancer
  • The application of atxn2l as a marker for auxiliary evaluation of secondary resistance to oxaliplatin in gastric cancer
  • The application of atxn2l as a marker for auxiliary evaluation of secondary resistance to oxaliplatin in gastric cancer

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0016] 1. Experimental materials

[0017] 1. Tissue specimens

[0018] Tissue section: Gastric cancer resection specimens were selected from Nanfang Hospital of Guangzhou Southern Medical University, including radical resection and palliative resection.

[0019] The inclusion criteria for pathological slides were: 1. Gastric cancer was confirmed by pathology; 2. Pathological slides were from the primary tumor of the stomach.

[0020] Exclusion criteria for pathological slides were: 1. Controversial pathological diagnosis; 2. Incomplete clinical treatment.

[0021] According to the patient's intraoperative condition and imaging examination, the patient was classified into TNM staging. According to the above criteria, a total of 48 cases of stage IV and 119 cases of stage I-III gastric cancer tissue samples were included for analysis. The samples were fixed with 10% formalin, embedded in paraffin, and sectioned.

[0022] Fresh gastric cancer specimens: Gastric cancer surgical...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention belongs to the field of functions and applications of genes and proteins, and relates to the new use of ataxin-2-like protein (ATXN2L) as a marker for assisting in evaluating the secondary drug resistance of gastric cancer to oxaliplatin. The present invention proves that the prognosis of gastric cancer patients with high ATXN2L expression is poor through clinical specimens. After silencing ATXN2L, the sensitivity of gastric cancer cells to oxaliplatin was enhanced. The oxaliplatin-resistant strain was obtained by in vitro induction, and the MTT experiment confirmed that the oxaliplatin-resistant strain was resistant to oxaliplatin and had a higher degree of malignancy. Western blot detection found that the expression of ATXN2L in oxaliplatin-resistant strains was higher than that in sensitive strains. In flow cytometry apoptosis assay, after silencing ATXN2L, the sensitivity of oxaliplatin-resistant cell lines to oxaliplatin increased. Therefore, ATXN2L can be used as a marker to assist in evaluating the secondary resistance to oxaliplatin in gastric cancer, so that the preparation process of the existing kit can be used to provide a kit for assisting in evaluating the secondary resistance to oxaliplatin in gastric cancer.

Description

technical field [0001] The invention belongs to the field of functions and applications of genes and proteins, and relates to a new application of ataxin-2-like protein (ATXN2L), in particular to the application of ATXN2L for preparing drugs for reversing gastric cancer oxaliplatin drug resistance. Background technique [0002] Gastric cancer is a common malignant tumor in my country, and chemotherapy is an important treatment in the comprehensive treatment of gastric cancer. The resistance of tumor cells to chemotherapy drugs limits the efficacy of chemotherapy and often leads to treatment failure in patients. Chemotherapy resistance includes primary drug resistance and secondary drug resistance. Primary drug resistance refers to the tumor’s own resistance to drugs before receiving drug treatment; secondary drug resistance refers to the tumor’s original non-resistant drug resistance. Emerging drug resistance. Solving the problem of primary drug resistance and secondary dr...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): G01N33/68
CPCG01N33/68
Inventor 廖旺军林立石敏潘常惬刘彦潭张俊浩
Owner NANFANG HOSPITAL OF SOUTHERN MEDICAL UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com